Gilead Sciences, Inc.

NASDAQ: GILD    
Share price (5/3/24): $65.33    
Market cap (5/3/24): $81.3 billion
13 Gilead Sciences, Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Credit Agreements Filter

EX-10.1
from 8-K 123 pages Term Loan Facility Credit Agreement ($6,000,000,000) Dated as of September 8, 2017 Among Gilead Sciences, Inc., as Borrower, Bank of America, N.A., as Administrative Agent, and the Other Lenders Party Hereto Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners and Wells Fargo Bank, National Association, as Syndication Agent
12/34/56
EX-10.5
from 8-K 123 pages Term Loan Facility Credit Agreement ($1,000,000,000) Dated as of January 12, 2012 Among Gilead Sciences, Inc., as Borrower, Bank of America, N.A., as Administrative Agent, the Other Lenders Party Hereto, Barclays Capital, as Syndication Agent and Goldman Sachs Bank USA, Jpmorgan Chase Bank, N.A., Royal Bank of Canada and Wells Fargo Bank, N.A., as Co-Documentation Agents Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital as Joint Lead Arrangers and Joint Bookrunners
12/34/56
EX-10.3
from 8-K 143 pages Short-Term Revolving Credit Facility Credit Agreement ($750,000,000) Dated as of January 12, 2012 Among Gilead Sciences, Inc., as Borrower, Gilead Biopharmaceutics Ireland Corporation, as Borrower, Bank of America, N.A., as Administrative Agent, the Other Lenders Party Hereto, Barclays Capital, as Syndication Agent and Goldman Sachs Bank USA, Jpmorgan Chase Bank, N.A., Royal Bank of Canada and Wells Fargo Bank, N.A., as Co-Documentation Agents Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital as Joint Lead Arrangers and Joint Bookrunners
12/34/56
EX-10.1
from 8-K 164 pages Five-Year Revolving Credit Facility Credit Agreement ($1,250,000,000) Dated as of January 12, 2012 Among Gilead Sciences, Inc., as Borrower, Gilead Biopharmaceutics Ireland Corporation, as Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the Other Lenders Party Hereto, Barclays Capital, as Syndication Agent and Goldman Sachs Bank USA, Jpmorgan Chase Bank, N.A., Royal Bank of Canada and Wells Fargo Bank, N.A., as Co-Documentation Agents Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital as Joint Lead Arrangers and Joint Bookrunners
12/34/56
EX-10.8
from 10-K 22 pages Amendment No. 2 to Amended and Restated Credit Agreement
12/34/56
EX-10.7
from 10-K 20 pages Amendment No. 1 to Amended and Restated Credit Agreement and Limited Consent and Waiver
12/34/56
EX-10.1
from 8-K 149 pages Amended and Restated Credit Agreement ($1,250,000,000) Dated as of December 18, 2007 Among Gilead Sciences, Inc., as Borrower, Gilead Biopharmaceutics Ireland Corporation, as Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the Other Lenders Party Hereto and Abn Amro Bank N.V., Citibank, N.A., and Deutsche Bank Securities Inc., as Co-Syndication Agents Banc of America Securities LLC, as Sole Lead Arranger and Sole Book Manager
12/34/56
EX-10.4
from 8-K 146 pages Credit Agreement ($200,000,000) Dated as of December 21, 2005 Among Gilead Sciences, Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the Other Lenders Party Hereto and Abn Amro Bank N.V., Citibank, N.A., Deutsche Bank Trust Company Americas, and Mizuho Corporate Bank (USA), as Co-Syndication Agents Banc of America Securities LLC, as Sole Lead Arranger and Sole Book Manager
12/34/56
EX-10.1
from 8-K 140 pages Term Loan Agreement ($300,000,000) Dated as of December 21, 2005 Among Gilead Biopharmaceutics Ireland Corporation as the Borrower, Bank of America, N.A., as Administrative Agent, the Other Lenders Party Hereto and Abn Amro Bank N.V., Citibank, N.A., Deutsche Bank Trust Company Americas, and Mizuho Corporate Bank (USA), as Co-Syndication Agents Banc of America Securities LLC, as Sole Lead Arranger and Sole Book Manager
12/34/56